Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment by Shafat, Manar S. et al.
1 
 
Leukemic blasts program bone marrow adipocytes to generate a pro-tumoral 
microenvironment 
 
Manar S Shafata, Thomas Oellerichb,c,d, Sebastian Mohrb, Stephen D Robinsone, 
Dylan R Edwardse,f, Christopher R Marleina, Rachel E Piddocka, Matthew Fenechf,g, 
Lyubov Zaitsevaa, Amina Abdul-Aziza, Jeremy Turnerf,g, Johnathan A Watkinsh, 
Matthew Lawesi, Kristian M Bowlesa,i, Stuart A Rushwortha, * 
 
aDepartment of Molecular Haematology, Norwich Medical School, The University of 
East Anglia, Norwich Research Park, NR4 7UQ, United Kingdom 
bDepartment of Medicine II, Hematology/Oncology, Goethe University, Frankfurt, 
Germany  
cGerman Cancer Research Center and German Cancer Consortium, Heidelberg, 
Germany 
dCambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell 
Institute, Department of Haematology, University of Cambridge, Cambridge, United 
Kingdom 
eSchool of Biological Sciences, The University of East Anglia, Norwich Research 
Park, NR4 7TJ, United Kingdom 
fNorwich Medical School, The University of East Anglia, Norwich Research Park, 
NR4 7UQ, United Kingdom 
gElsie Bertram Diabetes Centre, Norfolk and Norwich University Hospitals NHS 
Trust, Colney Lane, Norwich, NR4 7UY, United Kingdom 
hPILAR Research and Education, Cambridge, CB1 2RE UK 
iDepartment of Haematology, Norfolk and Norwich University Hospitals NHS Trust, 
Colney Lane, Norwich, NR4 7UY, United Kingdom 
 
Runinng title: Bone marrow adipocytes drive leukemic cell proliferation 
 
*Corresponding Author: email: s.rushworth@uea.ac.uk 
Dr Stuart Rushworth, Department of Molecular Haematology, Norwich Medical 
School, University of East Anglia, Norwich, NR4 7UQ,   United Kingdom:  Tel: +44 
(0)1603 591690   
 Blood First Edition Paper, prepublished online January 3, 2017; DOI 10.1182/blood-2016-08-734798
 Copyright © 2017 American Society of Hematology
For personal use only.on January 6, 2017. by guest  www.bloodjournal.orgFrom 
2 
 
Key Points 
• Bone marrow adipocytes support AML survival.  
• AML induces adipocyte lipolysis of triglyceride to free fatty acids and 
subsequent transport by FABP4. 
 
Abstract 
Despite currently available therapies most patients diagnosed with acute myeloid 
leukemia (AML) die of their disease. Tumor-host interactions are critical for the 
survival and proliferation of cancer cells; accordingly, we hypothesise that specific 
targeting of the tumor microenvironment may constitute an alternative or additional 
strategy to conventional tumor-directed chemotherapy. Since adipocytes have been 
shown to promote breast and prostate cancer proliferation, and because the bone 
marrow adipose tissue (MAT) accounts for up to 70% of bone marrow volume in 
adult humans, we examined the adipocyte-leukaemia cell interactions to determine if 
they are essential for the growth and survival of AML. Using in-vivo and in-vitro 
models of AML we show that bone marrow adipocytes from the tumor 
microenvironment support the survival and proliferation of malignant cells from 
patients with AML. We show that AML blasts alter metabolic processes in adipocytes 
to induce phosphorylation of hormone-sensitive lipase and consequently activate 
lipolysis, which then enables the transfer of fatty acids from adipocytes to AML 
blasts.  In addition, we report that fatty acid binding protein-4 (FABP4) mRNA is up-
regulated in adipocytes and AML when in co-culture. FABP4 inhibition using FABP4 
shRNA knockdown or a small molecule inhibitor prevents AML proliferation on 
adipocytes. Moreover, knockdown of FABP4 increases survival in Hoxa9/Meis1-
driven AML model. Finally, knockdown of carnitine palmitoyltransferase IA (CPT1A) 
in an AML patient-derived xenograft model improves survival. Here we report the first 
description of AML programming bone marrow adipocytes to generate a pro-tumoral 
microenvironment.  
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Introduction 
Survival of patients with acute myeloid leukemia (AML) is poor; two-thirds of young 
adults and 90% of older adults die of their disease.1 Improved outcomes will now 
only come from novel treatment strategies derived from an improved understanding 
of the biology of the disease. 
 
All mammals generate blood within their bones and AML arises from myeloid 
progenitors within the bone marrow (BM) microenvironment. AML blasts exhibit high 
levels of spontaneous apoptosis when cultured in vitro but have a prolonged survival 
time in vivo further indicating that the tissue microenvironment plays a critical role in 
promoting and maintaining AML cell survival.2-5  In human leukemias the 
microenvironment provides a number of soluble factors whose primary functions are 
to promote survival and homing,6,7 which implies that the apoptotic defect in AML is 
not cell-autonomous but highly dependent on extrinsic signals derived from the 
cellular microenvironment. These complex cell-cell interactions between AML blasts 
and the cells that support them within the bone marrow may therefore provide an 
attractive target for novel drug therapies. 
 
The BM microenvironment is defined by cell types not directly involved in 
haematopoiesis and include: macrophages; endothelial cells; osteoclasts; 
osteoblasts; adipocytes and fibroblasts. BM adipocytes were identified over a 
century ago, and bone marrow adipose tissue (MAT) accounts for up to 70% of BM 
volume of the axial skeleton in adult humans.8-10 MAT is an energy storage organ 
and consists primarily of triglycerides which can be broken down to release free fatty 
acids (FA) which in turn can be used to generate ATP. In cancer, a recent study by 
Cawthorn et al (2014), demonstrated that BM adiposity and circulating adiponectin 
increase in cancer therapy.8 Moreover, TNF and adiponectin from the BM of patients 
with AML inhibit normal hematopoiesis.11  However, although AML blasts are highly 
proliferative and grow within an adipocyte-rich environment, to date there is limited 
knowledge regarding the specific functions of BM adipocytes in relation to the 
proliferation and survival of AML.  
 
Adipocytes, in the context of solid malignancies, support tumor survival, proliferation 
and metastasis.12-14 In a study on breast cancer and the associated adipocytes 
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therein, Dirat et al. (2011) showed that these cancer associated adipocytes are 
greatly influenced by the invasive cancer cells with which they are associated.12 This 
study supports the concept of cancer cells orchestrating an environment which 
favours their progression through complex mechanisms by obtaining adipocyte 
participation. Furthermore, studies carried out in prostate cancer have demonstrated 
lipid transport between adipocytes and prostate cancer cells.13,15 In models of bone 
metastasis following prostate cancer, Herroon et al. (2013), show functional 
evidence of BM adipocyte support of tumor growth and identify fatty acid binding 
protein-4 (FABP4) as a key protein involved in the mechanism. While this study 
investigates FABP4 expression in the cancer cells, a separate study has investigated 
FABP4 expression in ovarian cancer associated adipocytes.14 FABP4 upregulation 
has been shown in the fat-rich omental metastases compared to the primary tumor 
site and mice lacking FABP4 show significant reduction in metastatic tumor growth, 
indicating the role of FABP4 in cancer proliferation and metastasis. Taken together, 
these studies identify a functional role for adipocytes and fatty acid transporters in 
the support of solid tumor metabolism and subsequent metastatic spread.  
 
In the present study, we look to identify whether adipocytes directly support the 
proliferation of human AML. Furthermore we evaluate the mechanisms controlling 
the interaction between AML blasts and MAT, as well as the downstream metabolic 
consequences in both the adipocytes and leukemia cells. Finally, we identify key 
regulators in the AML/MAT interaction and assess AML survival following targeted 
inhibition of this interaction.  
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Materials and Methods 
Materials 
Anti-phosphorylated HSL, anti-HSL, anti-HIS and anti-FABP4 were purchased from 
Cell Signalling Technology (Cambridge, MA, USA, Cat. 4126, 4107, 2365 and 3544 
respectively). Control-IgG-FITC, control-IgG-PE, control-IgG-APC, anti-CD34-PE, 
anti-CD90-FITC, anti-CD73-PE, anti-CD105-APC, anti-CD33-APC and anti-CD45-
FITC, antibodies were from Miltenyi Biotec (Bergisch Gladbach, Germany, Cat. 
130098847, 130098845, 130092214, 130098139, 130095403, 130095182, 
130094926, 130098043, 130098864). Lineage Cell Depletion Kit (mouse) was also 
purchased from Miltenyi Biotech (Cat 130090858).  Acipomox, etomoxir and FABP4 
inhibitor were purchased from R&D Systems (Abingdon, UK, Cat. 2784 and 4539). 
Recombinant FABP4-his was purchased from Abcam (Cambridge, UK Cat. 204760). 
All other reagents were obtained from Sigma-Aldrich (St Louis, MO, USA), unless 
otherwise indicated. 
 
Primary cell culture and differentiation 
Primary AML blasts and non-malignant CD34+ cells were obtained from patient bone 
marrow or blood following informed consent and under approval from the UK 
National Research Ethics Service (LRECref07/H0310/146). Cell isolation was carried 
out by density gradient centrifugation using Histopaque (Sigma-Aldrich, Cat. 1077) 
and cell type was confirmed by flow cytometry. All cells were grown in normal media 
(Dulbecco’s Modified Eagle’s Medium (DMEM) (ThermoFisher, Cat. 21885-025) 
supplemented with 20% foetal bovine serum (FBS) (ThermoFisher, Cat.10082139)) 
with or without the addition of cytokines purchased from Peprotech, UK, 100 ng/ml 
SCF (300-07), 50 ng/ml FLT3L (300-19), 20 ng/ml IL-3 (200-03) and 20 ng/ml G-CSF 
(300-23). Bone marrow stromal cells (BMSC) were isolated from AML bone marrow 
samples by adherence to tissue culture plastic and were then expanded in DMEM 
containing 20% FBS and supplemented with 1% penicillin-streptomycin 
(ThermoFisher, Cat 15140122). BMSC markers were confirmed using flow cytometry 
for expression of CD90+, CD73+, CD105+ and CD45-. 16 To induce adipocyte 
differentiation of BMSC (passage 2-4), a cocktail of dexamethasone (1μM), 
indomethacin (0.2mM), insulin (100nM) and 3-isobutyl-1-methylxanthine (0.5mM) 
(Cat. D4902, 17378, I9278 and I7018) in DMEM containing 10% FBS was prepared. 
The differentiation of BMSC to adipocytes was between 75%-95% as measured by 
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neutral lipid specific BODIPY® 493/503 dye (supplementary figure 1A and 
supplementary table 1). After differentiation, adipocytes and control BMSC were 
analysed for markers of adipocytes (adiponectin, FABP4 and CEBPa). Figure 3A 
and Supplementary figure 1B shows that differentiated adipocytes express higher 
levels of adiponectin, FABP4 and CEBPa than BMSC.  
 
Flow cytometry 
For this study we used the Accuri C6 (Bectin Deckinson, Oxford, UK) and the 
CyFlow Cube 6 (Sysmex, Milton Keynes, UK) for flow cytometry analysis. Cells were 
incubated for 5 minutes with the FCR receptor blocker (Miltenyi Biotec, Cat. 130-
059-901) and then stained with isotype controls or test antibodies (Miltenyi Biotec). 
Gates were set to the appropriate isotype control.  
 
Co-culture assay 
BMSC were seeded at 3 x104 cells per well of a 12 well plate and 1x104 for a 24 well 
plate in normal growth media. Cells were left to adhere and proliferate until maximum 
confluency. Growth media was replaced with differentiation media which was 
replaced every four days until day 21. Differentiated adipocytes were washed twice 
with normal growth media and then placed in normal growth media until co-culture 
experiment. For co-culture experiments AML cells were placed on the adipocytes at 
5x105 (per well of 12 well plate) and 1x105 (per well of a 24 well plate) in normal 
growth media.  Adipocyte/AML co-cultures were then incubated for indicated time 
points and Supplementary Table 2 shows the combination of different samples used 
for each experiment. All co-cultures were from different patients, at no point were 
autologous co-cultures performed. To isolate adipocytes from co-culture 
experiments, all suspension cells were removed by gentle pipetting and washing with 
PBS. This was then followed by light trypsinisation where diluted typsin with PBS 
(1:1) for 40 seconds followed by gentle tapping. All suspension cells where removed 
and adhered adipocytes were washed with PBS and then lysed using RNA or protein 
lysis buffer. 
 
Lentiviral knockdown 
MISSION pLKO.1-puro Control Vector, catalogue number SHC001 was used as the 
lentivirus control (Control shRNA). Plasmids containing MISSION® shRNA 
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TRCN0000418254 (human FABP4 shRNA), TRCN0000105185 (mouse FABP4 
shRNA), TRCN0000036279 (human CPT1A shRNA), TRCN and were purchased 
from Sigma-Aldrich and viruses were produced as previously described.17 Lentiviral 
stocks were concentrated using Amicon® Ultra centrifugal filters (Cat. UFC910024) 
and titres were determined using Lenti-X™ qRT-PCR titration kit (CloneTech Cat. 
631235). Stromal cells were plated at a density of 3x104/well in a 12 well plate, 
expanded and differentiated into adipocytes. Adipocytes were then infected with 
FABP4 shRNA lentiviral stock at an MOI of 20. Human and mouse AML cells were 
infected with respective lentiviral stocks at an MOI of 20 in the presence of polybrene 
(10µg/ml final). Infected cells were analysed using real-time PCR (Roche) and 
Western blotting. 
 
Patient-derived AML xenograft 
For this study the NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ (NSG) from The Jackson 
Laboratory, Bar Harbour, ME, USA were used. The NSG mice were maintained 
under specific pathogen-free conditions in the research animal facility of The 
Disease Modelling Unit, The University of East Anglia, Norwich, UK. All animal 
experiments were performed in accordance with UK Home Office regulations.  
 
Engraftment of primary AML cells in NSG mice 
6-8x106 isolated AML blasts were grown in mono culture and 2x106 isolated AML 
blasts grown on adipocytes for 6 days, 2x106 viable AML cells were washed and 
subsequently resuspended in PBS. Cells were then injected into the tail vein of non-
irradiated 6-8 week old female NSG mice. When clinical signs of illness became 
apparent (rough fur, hunchback, or reduced motility) or if 12 weeks post injection 
was reached, mice were sacrificed by exposure to CO2. BM and spleen were 
harvested and analysed for human CD33 and CD45. If more than 1% of human 
CD45/CD33 cells were detected in the BM or spleen, the AML sample was said to be 
engrafted.  For AML grown in cytokine supplemented media, 2x106 viable AML 
grown in normal media with the addition of cytokines (100 ng/ml SCF (Peprotech 
300-07), 50 ng/ml FLT3L (Peprotech 300-19), 20 ng/ml IL-3 (Peprotech 200-03) and 
20 ng/ml G-CSF (Peprotech 300-23). 
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For the CPT1-KD experiment, isolated primary AML were grown on adipocytes for 6 
days. The AML cells were removed from the adipoyctes and then infected with a 
control-shRNA or  CPT1-shRNA lentivirus and after 96 hours cells were expanded 
on the adipocytes and 2x106 primary AML cells were then injected into the tail vein of 
non-irradiated 6-8 week old female NSG mice.  
 
Retroviral AML transplantation mouse model 
C57BL/6J mice were obtained from Janvier-Labs (Le Genest-Saint-Isle, France). All 
animal experiments were performed according to national and international 
standards and had been approved. Bone marrow cells were harvested from mice, 
and lineage-negative cells were obtained by negative selection using the Lineage 
Cell Depletion Kit (mouse) as recommended by the manufacturer. Lineage-negative 
cells derived from C57BL/6J were retrovirally infected by co-culture with GP+E86 
cells in the presence of polybrene (10 µg/ml, Sigma-Aldrich, Munich, Germany). Co-
culture with GP+E86 packaging MSCV-Hoxa9-PGK-neo was performed for 3 days 
followed by co-incubation with GP+E86 MSCV-Meis1-IRES-YFP for 1 day. Hoxa9 
cells were selected with 0.6 mg/ml G418 (Sigma-Aldrich) for at least 5 days. After 
selection, cells were sorted with a FACS BD Aria III cell sorter. Lentiviral 
transductions of cultured cells with vectors encoding FABP4-specific shRNA and 
control shRNA were performed as described previously.18 8x104 cells were 
transplanted together with 2x105 support cells by injection into the tail vein of lethally 
irradiated (9.5 Gy) recipient mice (C57BL/6J). Support cells were isolated from 
C57BL/6J mice and purified on a Ficoll gradient. To perform in vitro assays with 
Hoxa9/Meis1 expressing cells, cells were cultured in DMEM supplemented with 20% 
FBS and supplemented with the following cytokines murine SCF (cat. 250-03; 
100ng/ml final), IL-6 (cat. 200-06; 10ng/ml final) and IL-3 (cat.213-13; 10ng/ml final).  
 
Immunocytochemistry 
AML-adipocyte niches formed in the BM were isolated from patient samples and 
grown on chambered tissue culture treated slides (12 well chamber, removable – 
Ibidi cat. 81201). Niches were then fixed with 4% PFA, permeabilised with 0.01% 
Triton and blocked with goat serum. Cells were stained with neutral lipid specific 
BODIPY® 493/503 (4,4-Difluoro-1,3,5,7,8-Pentamethyl-4-Bora-3a,4a-Diaza-s-
Indacene) dye, CD90 and DAPI. AML blasts were removed and stained with neutral 
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lipid specific BODIPY® 493/503 and CD34 antibody. Images were visualised with 
secondary Alexa Flour 568 or 488 conjugate immunoglobulin G (Invitrogen). Nuclei 
were stained with 4’6-diamidino-2-phenylindole before samples were mounted with 
Fluoromount aqueous mounting medium (Sigma Cat. F4680). Cells were imaged by 
an AxioCam ICm1 monochrome CCD camera attached to the Apotome.2 Imaging 
System and confocal microscopy (Zeiss LSM 800 with Airyscan) using Axiovision 
4.8.2 software (Carl Zeiss). Image staining intensities were analysed with ImageJ 
software. 
 
Proliferation, cell cycle and death assays 
Treated primary AML blasts were incubated with 5-bromo-2’–deoxyuridine (BrdU 
staining kit, eBioscience, Cat. 8811-6600) and CD34 antibody. The proliferation 
percentage of cycling AML blasts were analysed using flow cytometry. Cell cycle 
analysis of AMLs from monoculture and co-culture was carried out by ethanol 
fixation and propidium iodide staining and quantified using flow cytometry. AML 
apoptosis was measured using PI/AnnexinV (eBiosciences, Cat. 88-8005-72) and 
was also quantified using flow cytometry. 
  
Free fatty acid and glycerol detection 
Free fatty acid and glycerol detection was performed using a lipolysis assay kit for 
detection of both free glycerol and fatty acids (Zenbio, Research Triangle, NC, Cat. 
LIP-2-NC). AMLs were cultured with adipocytes in LIP2/3 assay buffer and incubated 
for 24 hours at 37C. Media was assayed to detect free fatty acid and glycerol 
according to manufacturer’s specifications. 
 
Free fatty acid uptake assay 
For lipid visualisation and transfer, adipocytes were incubated with dodecanoic acid 
fluorescent fatty acid analogue (DAA) (QBTTM Fatty acid uptake assay kit, Molecular 
Devices, Cat. R6138) for 3 hours and washed three times in PBS. Primary AML 
blasts were then cultured alone or with labelled adipocytes for 24 hours. AML blasts 
were then removed and fluorescence was subsequently measured by flow cytometry 
to indicate transfer of fluorescent labelled fatty acid from adipocytes to AML.  
 
Real-time PCR 
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Total RNA was extracted from co-cultured BMSC, adipocytes and AMLs and from 
monoculture of the same using Nucleic Acid PrepStation from Applied Biosystems 
(Cat. 6100). RNA PCR core kit was used for reverse transcription. SYBR green I dye 
(Roche, Cat. 04887352001) was used for real-time quantitative PCR using human 
FABP4 (F: CCACCATAAAGAGAAAACGAG, R: AGTTGCTTGCTAAATCATGG), 
human GAPDH (F: CTTTTGCGTCGCCAG, R:TTGATGGCAACAATATCCAC),  
human CPT1 (F:TGGATCTGCTGTATATCCTTC, R: AATTGGTTTGATTTCCTCCC), 
Mouse FABP4 ( F: GTAAATGGGGATTTGGTCAC, R: 
TATGATGCTCTTCACCTTCC). Mouse GAPDH (F: AAGGTCATCCCAGAGCTGAA, 
R: CTGCTTCACCACCTTCTTGA) primers.  
 
Western immunoblotting 
Western analyses following SDS-PAGE were carried out as described. Whole cell 
lysates were extracted from AML/adipocyte co-culture and monocultures by using 
radioimmunoprecipitation assay buffer (RIPA) containing 1% NP-40 (Sigma-Aldrich, 
Gillingham, UK), 50 mmol/L Tris, 10% glycerol, 0.02% NaN3, 150 mmol/L NaCl, and 
a cocktail of phosphatase and protease inhibitors (Sigma-Aldrich, Gillingham, UK). 
SDS-Page was performed as previously described. 17,19  
 
Bioinformatic analysis 
Publicly available RNA sequencing data were downloaded for a panel of 43 AML 
patients, which comprised 22 AML samples obtained from peripheral blood and 21 
AML samples obtained from bone marrow aspirate and for 17 non-malignant CD34+ 
from 17 non-pooled individuals (Gene Expression Omnibus Accession ID: 
GSE49642 and GSE48846).20 Data were available as Reads Per Kilobase per 
Million mapped reads (RPKM). RPKM data for FABP4 were extracted and processed 
further by first replacing zero-valued entries with one followed by logarithmic 
transformation to the base 2.21 FABP4 RPKM values for blood, bone marrow 
samples and non-malignant CD34+ cells were compared with a Wilcoxon rank-sum 
test. 
 
Clonogeneic methylcellulose assay 
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Primary AML blasts from adipocyte co-culture and monoculture were plated in 
methylcellulose medium (R&D Systems) at a density of 1 x 104 in all experiments. 
Colonies were visualised and counted after 14 days. 
 
Fatty acid oxidation 
β-oxidation of fatty acids was assessed using the Seahorse XFp Analyzer and the 
Seahorse XF Palmitate-BSA FAO Substrate kit (Agilent Seahorse Bioscience) 
according to manufacturer’s specifications. Briefly, AML blasts or non-malignant 
CD34+ cells were cultured with or without adipocytes and then removed from co-
culture and placed in substrate limited media (supplemented with 0.5mM glucose, 
0.5mM carnitine, 1mM glutamine and 1% FBS) for 4 hours before assaying. AML 
blasts were then plated in poly-D-lysine (Sigma) coated assay wells at a density of 
2x105 per well in base media containing 2.5mM glucose, 0.5mM carnitine and 5mM 
HEPES and adjusted to pH7.4 with 1N NaOH. ETX (40µM) or BSA and 
Palmitate:BSA where added into the injection ports. The experimental template was 
designed using Wave software for desktop from Seahorse Bioscience. 
 
Statistical analysis 
We used the Mann-Whitney U test to compare results between groups unless 
otherwise stated in the legends. Results with P < 0.05 were considered statistically 
significant (denoted by *). Results represent the mean ± Standard Deviation of 4 or 
more independent experiments. For Western blotting, data are representative 
images of 3 independent experiments. We generated statistics with Graphpad Prism 
5 software (Graphpad, San Diego, CA, USA). 
  
For personal use only.on January 6, 2017. by guest  www.bloodjournal.orgFrom 
12 
 
Results 
BM Adipocytes support the survival and proliferation of primary AML. 
Cellular proliferation is a highly energy-intensive process. Since adipocytes store 
energy in the form of triglycerides, we hypothesised that adipocytes provide energy 
in the form of fatty acids (FA) to AML blasts to support rapid growth. Initially, to 
determine the presence of lipids in AML we examined freshly isolated AML cells for 
lipid stores using the neutral lipid dye (BODIPY® 493/503) and find that freshly 
isolated AML cells (CD34+) contain abundant lipids (figure 1A). Figure 1B and 1C 
shows that lipid stores using the neutral lipid dye are depleted in AML and non-
malignant CD34+ cells when cultured in vitro.  Supplementary Figure 2 show that 
AML lose lipid content even when co-cultured with BMSC. As primary AML cells 
undergo spontaneous apoptosis when cultured in vitro to determine if adipocytes can 
support the survival of primary AML we cultured primary AML blasts, either alone or 
in co-culture with adipocytes derived from BM mesenchymal progenitor cells. Figure 
1D and Supplementary Figure 3A show that primary AML blasts co-cultured with 
adipocytes (n=11) are protected from undergoing apoptosis for up to 6 days when 
compared to AML blasts cultured alone.   
 
Next we wanted to determine if BM adipocytes can support the proliferation of 
primary AML blasts. Primary AML blasts increase in number when co-cultured with 
BM adipocytes for 6 days, compared to AML monoculture and AML cultured on 
BMSC (n=12) (figure 1E). Figure 1F shows that adipocytes also support non-
malignant CD34+ cell survival. Supplementary Figure 3B and 3C show that 
adipocytes support AML proliferation as measured by BrdU incorporation.  
Supplementary figure 4 shows AML blasts on BMSC and adipocytes from the same 
patient. In AML blast colony forming cell (CFC) assays, adipocyte co-culture 
promoted CFC growth when compared to AML mono-culture (Figure 1G). Finally we 
showed that primary AML blasts from patient samples (n=4) which had been cultured 
on BM derived adipocytes for 6 days reliably engrafted NSG mice (Figure 1H). The 
same AML cells cultured in isolation did not engraft NSG mice after 12 weeks. AML 
were stained for CD33 and CD45 to confirm cell identity.16,22  We also examined the 
effect of cytokines on AML survival compared to co-culture with adipocytes. 
Supplementary Figure 5A shows that there is a significant increase in survival of 
AML when cultured on adipocytes compared to with a media supplemented with 
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cytokines. Supplementary Figure 5B shows that adipocytes support the engraftment 
of AML blasts compared to AML grown with cytokines. Taken together, these results 
show that adipocytes maintain AML progenitor cells. 
 
AML blasts induce adipocyte lipolysis.  
Our results indicate that adipocytes confer a proliferative advantage to primary AML. 
We hypothesized that this could be due to transfer of FA from the adipocytes to 
AML. Therefore, to understand the effect AML cells have on adipocytes we assessed 
FA and glycerol release.  Co-culture of AML with adipocytes increases FA and 
glycerol release compared to adipocyte and AML alone. (Figure 2A). Moreover, non-
malignant CD34+ cells could also induce lipolysis of adipocytes, albeit at a much 
reduced quantity compared to AML (Figure 2A). Supplementary figure 6A shows that 
conditioned media from AML can also induce adipocyte lipolysis.  Moreover, Figure 
2B shows that when we culture AML blasts with the FA, oleate, this supports the 
survival of AML. Lipolytic activation of adipocytes results from the phosphorylation of 
hormone sensitive lipase (HSL).  Figure 2C shows that AML induced phosphorylated 
HSL (pHSL) in adipocytes. Conversely, acipomox (which is known to inhibit lipolysis, 
by inactivation of AMP activated protein kinase and downstream pHSL) inhibited 
AML proliferation when cultured on adipocytes but not alone or on BMSC (Figure 
2D). Supplementary Figure 7 shows that adipocytes have significantly more HSL 
mRNA expression compared to BMSC and AML. To determine if lipids detected in 
the tumor cells after co-culture were derived from adipocytes, we cultured primary 
AML blasts with either adipocytes or BMSC that had previously been loaded with a 
fluorescent lipid dye (DAA). Supplementary Figure 8 shows loading of DAA into both 
BMSC and adipocytes. During co-culture we observed that lipids were transferred 
from adipocytes to AML (Fig. 2E, 2F and Supplementary Figure 9), moreover this 
transfer was inhibited by acipomox, thus supporting a model in which adipocytes 
provide lipids to support tumor growth.  
 
 
FABP4 is important for the transfer of lipids from adipocytes to AML  
FABP4 is a carrier protein for FA expressed in adipocytes,23 and supports the 
movement of long chain fatty acids generated by lipolysis to the extracellular 
membrane and beyond.24,25 Additionally, increased FABP4 has been shown to be 
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involved in the transfer of FA from adipocytes to breast and ovarian cancer cells.12,14 
We therefore examined the expression of FABP4 in human adipocytes and BMSC 
cultured with AML blasts or non-malignant CD34+ cells. RNA expression data shows 
that FABP4 levels are increased in adipocytes but not BMSC when cultured with 
AML, moreover non-malignant CD34+ cells had no effect on adipocyte FABP4 
mRNA expression (Figure 3A). We also found that AML conditioned media could 
induced FABP4 up regulation in adipocytes (Supplementary Figure 10A). Next we 
examined if other genes associated with lipolysis were also induced in adipocytes 
when cultured with AML. Supplementary Figure 11A shows that ATLG and MGLL 
mRNA expression are not changed in adipocytes when cultured with AML. In an 
apparent paradox, when the expression of FABP4 protein was examined, a 
reduction was observed in adipocytes cultured with AML compared to adipocytes 
alone (Figure 3B).  FABP4 is known to be released from adipocytes as they transport 
the FA,26 therefore FABP4 expression in the culture media was measured by a 
FABP4 specific ELISA. Figure 3C shows that culturing AML with adipocytes induces 
a release of FABP4 into the culture media. To determine if the FABP4 released by 
the adipocyte is taken up by the AML we used a recombinant FABP4 tagged to a His 
sequence. AML were cultured with and without the recombinant FABP4 for 4 hours. 
Figure 3D shows that no recombinant FABP4 was detected in AML. Next we 
examined if we could prevent the increase of lipids in AML blast by knockdown of 
FABP4 in the adipocyte. Figure 3E shows the knockdown FABP4 protein in 
adipocytes and figure 3F demonstrates that knockdown of adipocyte FABP4 
inhibited the transfer of lipids to AML. Furthermore, FABP4 chemical inhibitor 
(BMS309403) inhibits AML blast survival but had no effect on non-malignant CD34+ 
cells (Figure 3G). Finally, FABP4 lentiviral knockdown in adipocytes (Figure 3H) 
inhibits AML blast survival. Together these results demonstrate that FABP4 is critical 
for the transfer of FA from adipocytes to AML blasts. 
 
As Herroon and colleagues have shown that FABP4 in prostate cancer cells is 
upregulated in response to culture with adipocytes,15 we next examined whether 
FABP4 expression levels were elevated in AML cells extracted from bone marrow as 
compared to AML cells extracted from peripheral blood or non-malignant CD34+ 
cells. We found FABP4 expression to be significantly higher in AML bone marrow 
samples than in AML from peripheral blood or non-malignant CD34+ cells (P < 
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0.001, Wilcoxon rank-sum test) (Figure 4A). To confirm that this upregulation of 
FABP4 was a result of AML interacting with adipocytes rather than BMSC we 
examined FABP4 expression in AML cultured alone, with adipocytes or BMSC. 
Supplementary figure 12 shows the purity of AML after separation from adipocytes 
co-culture.  Figure 4B shows that FABP4 RNA is upregulated in AML in response to 
co-culture with adipocytes but not BMSC. We determined whether knockdown of 
FABP4 in AML cells could reduce survival when cultured on adipocytes. Figure 4C 
shows that FABP4-KD AML cells have reduced viability when co-cultured with 
adipocytes compared to co-culture with BMSC. Furthermore knockdown of AML 
FABP4 inhibited the transfer of lipids from adipocytes to AML (figure 4D).   
 
Next, we sought to determine the functional role of FABP4 in an AML mouse model. 
To do this we used a retroviral AML transplantation model where Hoxa9 and Meis1 
are used to transform myeloid progenitor cells as described by Kroon et al (1998).27 
Initially we determined if Hoxa9/Meis1-expressing cells could proliferate on 
adipocytes compared to BMSC or monoculture or monoculture without cytokine 
supplements. Figure 4E shows that Hoxa9/Meis1-expressing cells proliferate on 
adipocytes and BMSC. Next we knocked down FABP4 in Hoxa9/Meis1-expressing 
cells (figure 4F) and found that FABP4 KD reduced AML survival when cultured with 
adipocytes compared to media supplemented with cytokines or BMSC (Figure 4G). 
Moreover, knockdown of FABP4 in Hoxa9/Meis1-expressing cells also reduces FA 
uptake, quantified by DAA fluorescence, when tumor cells were cultured on 
adipocytes (Figure 4H). Finally we show in vivo that FABP4-KD in Hoxa9/Meis1 
expressing blasts significantly increases animal survival (Figure 4I). Taken together 
these results demonstrate that FABP4 in AML is essential for FA transport and tumor 
proliferation in the BM microenvironment.   
 
Co-culture of AML with adipocytes activates β-oxidation in AML blasts 
In order to study the reliance of AML blasts on adipocytes for their energy we first 
measured the cellular oxygen consumption rate (OCR) in AML blasts to determine 
levels of fatty acid oxidation (FAO). To confirm that AML blasts can use oxidation of 
exogenous fatty acid we assessed FAO by monitoring OCR upon addition of 
palmitate (FAO substrate) followed by addition of etomoxir (FAO inhibitor - ETX). 
Figure 5A shows that primary AML have increased OCR in the presence of palmitate 
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which is inhibited by ETX this is compared to non-malignant CD34+ cells. Oxidation 
of exogenous fatty acid can be measured by examining OCR of AML blasts and non-
malignant CD34+ cells in response to ETX. Figure 5B and Supplementary Figure 13 
shows that AML blasts cultured with adipocytes have increased FAO compared to 
AML blasts cultured alone or with BMSC and non-malignant CD34+ cells. In addition, 
we observed that AML blasts cultured on adipocytes had greater basal OCR 
compared to AML cultured alone or on BMSC (Figure 5C).  OCR was reduced in 
AML co-cultured on adipocytes compared to BMSC with FABP4 knocked down 
compared to control KD cells (Figure 5D). Moreover, because of the nature of the 
OCR experiment in which AML were serum starved for 4 h prior to being loaded onto 
the Seahorse Bioanalyser we show that AML FABP4 mRNA levels were stable 
compared to non serum starved AML cells (Supplementary Figure 10B). In addition, 
the FAO inhibitor ETX reduced AML blast survival when grown on adipocytes but not 
on BMSC (figure 5E). 
 
ETX is a selective inhibitor of carnitine palmitoyltransferase-1 (CPT1A), which 
transports fatty acyl chains from the cytosol into the mitochondria, a process 
essential for the production of ATP from fatty acid oxidation.28  We therefore 
examined the expression of various genes including CPT1A in AML when cultured 
with adipocytes.  Supplementary Figure 11B shows that CPT1A, CPT2 and ACADL 
are all up-regulated in AML when cultured with adipocytes. Accordingly, we knocked-
down CPT1A in AML blasts. Figure 5F shows a reduction in CPT1A mRNA and 
protein in human AML cells after infection with CPT1A shRNA lentivirus. Following 
successful knockdown of CPT1A in AML cells we found that CPT1A-KD AML cells 
have reduced viability when cultured with adipocytes compared to cells cultured on 
BMSC (Figure 5G). Finally, we tested the effect of CPT1A-KD in an AML patient 
derived xenograft model. Figure 5H shows that NSG mice engrafted with CPT1A-KD 
AML blasts from 2 patient samples have increased survival compared to control-KD 
NSG mice (n=4). Supplementary Figure 14 shows the bone marrow and spleen 
engraftment data for Figure 5H. 
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Discussion 
Here we report that bone marrow adipocytes support the survival and proliferation of 
AML blasts. We find that AML induces lipolysis of triglyceride stored within BM 
derived adipocytes. Subsequently the FA released by triglyceride lipolysis within 
adipocytes is transported out of the adipocyte in a process dependent on the 
chaperone protein FABP4. Proximity to adipocytes also results in up-regulation of 
the same chaperone protein, FABP4, within the blasts, which is then used to 
transport adipocyte derived FA to the mitochondria within the tumor cells. The AML 
mitochondria use the FA as a substrate for B-oxidation generating the energy 
required for leukemic growth and proliferation.  
AML arises from malignant transformation and proliferation of hematopoietic 
progenitor cells in the BM microenvironment. AML is co-located with BM adipose 
tissue (MAT), which is a biologically active energy storage and endocrine organ and 
accounts for approximately 70% of bone marrow volume in adult humans.8,29 Like 
the prevalence of AML, BM adipocytes are known to increase with age and 
furthermore are not merely passive occupants of the bone marrow but are now 
appreciated to be actively involved in processes linked to bone metabolism, 
osteoporosis, inflammation and regulation of the hematopoietic niche.30 Moreover, 
adipocytes have been shown to support the proliferation of solid tumor cells in 
studies of breast, ovarian and prostate cancer metastases.12,14,15 Here we describe 
the pro-tumoral function of bone marrow derived adipocytes in AML.  
We report that leukemia cells cause functional changes in non-malignant adipocytes, 
which ultimately leads to the transfer of free fatty acids from adipocytes to the AML 
blast. This is a FABP4 dependent process. FABP4 has intracellular functions in 
adipocytes but is also known to be actively secreted by adipocytes where it can exert 
specific biological functions in tissues other than it’s origin.31 Co-culture of AML and 
adipocytes results in transcriptional up-regulation of FABP4, in both in the adipocyte 
and the leukemic blast. Curiously however, we found that despite this transcriptional 
increase of FABP4 in the adipocytes, the intra-adipocyte protein level of FABP4 is 
decreased upon co-culture with AML. This led us to hypothesise that either (1) 
adipocyte FABP4 rapidly chaperones the FA from the adipocyte into the 
microenvironment (2) adipocyte FABP4 rapidly chaperones the FA from the 
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adipocyte into the AML cells or (3) excess intracellular FABP4 is simply degraded 
within the adipocyte. To consider this further we investigated the levels of FABP4 in 
the media of AML adipocyte co-cultures and confirmed FABP4 was released into the 
medium. In models of prostate cancer recombinant FABP4 is taken up by the 
malignant cells.32 In our studies we also conducted experiments using recombinant 
FABP4 to determine if AML blasts actively take up this protein. We showed that no 
recombinant FABP4 was detected in AML after 4 hours of culture. These data 
suggest that unlike prostate cancer FA/FABP4 is not directly transferred from 
adipocyte to the AML cell but may be involved in an extracellular-to-membrane 
transport whereby it is degraded after functionality outside of the cell. Further studies 
would need to be conducted to confirm this hypothesis. 
Maintenance of AML appears to depend on both the adipocyte and the leukemic 
blast being able to generate FABP4. Pharmacological inhibition or lentiviral-
knockdown of FABP4 in the adipocytes showed a significant inhibitory effect on AML 
survival in co-culture experiments. Fatty acid binding proteins bind free FA, which 
otherwise in their free form are relatively insoluble and potentially toxic. Furthermore, 
FABP4 binds and donates its fatty acid ligand via collisional interactions with 
membranes and is actively secreted from adipocytes.31,33 We suggest that the 
reduced AML survival on FABP4 KD adipocytes is due to the inability of FA to be 
secreted from the adipocytes in the absence of FABP4 protein. In addition we 
observed that FABP4 knock down in the AML cells improved survival in our in-vivo 
models (although was unable to ultimately prevent leukemic engraftment). We also 
compared FABP4 transcript levels between AML blasts taken from the bone marrow 
and the peripheral blood, and found that FABP4 was enriched in AML cells collected 
from the adipose rich environment of the BM, indicating that FABP4 expression in 
AML blasts requires an external BM derived signal. Taken together we propose that 
in AML, FA is transported in the BM adipocyte by adipocyte derived FABP4, then 
secreted and taken up by the AML and transported within the AML by AML derived 
FABP4. We conclude that delivery and intracellular transport of FA to and in AML 
blasts is dependent on the presence of functional bone marrow adipocytes.  
When we compare our in vitro FABP4 knock down experiments in primary human 
AML cells and HoxA9/Meis1 cells, the effect in the HoxA9/Meis1 experiments is 
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comparatively modest. However, in contrast when FABP4 was knocked down in 
HoxA9/Meis1 cells, which were then injected into mice, we observed a more 
demonstrable anti-tumor effect. In addition we also found that our AML blasts 
maintained on adipocytes appeared to engraft (range 4-6 weeks) earlier than 
expected when compared to other reports in which primary AML blasts had not been 
previously cultured on adipocytes.34-36  We have not investigated this observation 
formally but postulate that adipocytes may support the maintenance of primary 
leukemic progenitor cells. Overall, we suggest that our in-vivo model more closely 
recapitulates the complexity of a tumor growing within a patient than the in-vitro 
assays and also propose that adipocytes may improve efficiency of ex-vivo culture 
systems for primary human AML. 
Blocking lipolysis using Acipomox or inhibiting transfer of free fatty acids using a 
FABP4 inhibitor only decreased AML viability between 40–60%. This could in part be 
due to the efficiency of the drug to inhibit its target. Alternatively perhaps this implies 
that adipocytes contribute other pro-AML survival factors in addition to free fatty 
acids. Adipocytes have been shown to secrete pro-inflammatory cytokines in the 
presence of malignant cells which may have an impact on tumor cell migration and 
survival.37 This has specifically been shown in the context of leukemias by Ye and 
colleagues, who report that bone marrow and gonadal adipose tissues show high 
levels of tumor associated pro-inflammatory cytokine secretion, several of which had 
previously been implicated in tumor cell migration.37-39 Therefore, it is likely that BM 
adipocytes provide more than just FA to AML to facilitate the proliferative capacity of 
this disease.  
We found that the OCR of AML cells increased in adipocyte co-culture experiments 
and that inhibition of CPT1A in the leukemic cells then significantly reduced AML 
OCR and survival. CPT1A is essential for the transfer of FA to the inner 
mitochondrial membrane for acetyl-CoA generation via B-oxidation,40  and these 
data indicate that the BM adipocytes are a source for the FA necessary for AML 
metabolism. Our observations are also consistent with the work of others who have 
previously reported the importance of β-oxidation in AML survival and 
proliferation.41,42 Conversely, in control experiments, non-malignant CD34 positive 
cells did not appear to significantly decrease their OCR upon treatment with the 
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CPT1A inhibitor, etomoxir, indicating that this FA oxidation signature is particularly 
associated with leukemic progenitors.  
In summary, although adipocytes in the non-malignant setting appear to be negative 
regulators of hematopoietic microenvironment.43 in the context of disease, 
adipocytes like other cells, can undergo distinct pathologic changes.44 Here we 
report that in the setting of AML, BM derived adipocytes support tumor proliferation 
and survival. Specifically, AML blasts modulate intra-cellular adipocyte metabolism 
into a lipolytic state resulting in the release of FA into the microenvironment. 
Ultimately, this free fatty acid is metabolically beneficial to the leukemia. Accordingly, 
we hypothesise that identification of this pro-tumoral interaction will open up potential 
novel therapeutic strategies in the treatment of human AML.  
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Table 1. AML patient sample information used in this study. This table defines 
the nature of the AML disease including WHO diagnosis and cytogenetics.   
Number Age Sex WHO diagnosis Cytogenetics % blasts 
      
AML#1 69 M AML NOS N/A 60 
AML#2 66 F AML without maturation Trisomy 9 90 
AML#3 41 F AML with t(6;9)(p23;q34); 
DEK-NUP214 
t(6;9) 95 
AML#4 62 M AML with maturation complex 55 
AML#5 70 M AML with maturation Normal 80 
AML#6 70 M AML without maturation Complex 95 
AML#7 91 F AML NOS N/A 60 
AML#8 55 F AML Not avaiable 70 
AML#9 59 F AML with t(8;21)(q22;q22) 
RUNX1-RUNX1T1 
t(8;21) 80 
AML#10 78 F AML without maturation Normal 95 
AML#11 58 F AML with maturation Normal 80 
AML#12 65 M AML with maturation Trisomy 13 30 
AML#13 73 F AML without maturation Normal 95 
AML#14 49 M AML with myelodysplasia 
related changes 
N/A 55 
AML#15 64 F AML with myelodysplasia 
related changes 
Normal 45 
AML#16 65 M AML with minimal 
differentiation 
Normal 95 
AML#17 23 F AML without maturation t(5;12) 95 
AML#18 37 M AML without maturation Normal 90 
AML#19 59 M AML with t(8;21)(q22;q22) 
RUNX1-RUNX1T1 
t(8;21) 60 
AML#20 65 M AML with maturation Not available 70 
AML#21 68 M Therapy related AML Not available 40 
AML#22 63 M AML with myelodysplasia 
related changes 
Not available 30 
AML#23 76 M AML without maturation Not available 95 
AML#24 75 M AML with maturation Complex 55 
AML#25 88 M AML with maturation Trisomy 8 30 
AML#26 35 M AML without maturation 46 XY 80 
AML#27 72 M AML with myelodysplasia  
related changes 
46,XY,isochrome 
(17)(q10) 
90 
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Figures Legends 
 
Figure 1. BM adipocytes support the survival and proliferation of primary AML. 
(A) Immunofluorescence of primary AML blasts stained for CD34+ (red) and neutral 
lipids (green) using BODIPY® 493/503. All images are representative of 6 AML 
patient samples. Scale bar = 10 micron (B) Freshly isolated AML, AML cultured for 1 
day and AML cultured for 2 days stained with the neutral lipid BODIPY® 493/503 dye 
and analysed by flow cytometry. Data represented as mean ± standard deviation. (C) 
Freshly isolated non-malignant CD34+ cells and freshly isolated AML samples 
stained with the neutral lipid BODIPY® 493/503 dye and analysed by flow cytometry.  
(D) AML patients samples in monoculture and co-cultured with bone marrow-derived 
adipocytes for 6 days and then stained with PI/Annexin V. The line through the data 
indicates the median. (E) AML blasts incubated alone or with adipocytes or BMSC 
for 6 days and AML blasts counted using flow cytometry and trypan blue exclusion 
(n=12). The line through the data indicates the median (F) Non-malignant CD34+ 
cells cultured alone or in co-culture with BMSC or adipocytes and CD34+ cell 
counted using flow cytometry and trypan blue exclusion (n=5). The line through the 
data indicates the median (G) AML blasts from 3 different patients were cultured 
alone or with adipocytes or BMSC for 6 days and then placed in a colony forming cell 
(CFC) assay for 15 days. Colonies were then counted.  Data represented as mean ± 
standard deviation (H) 2x106 primary AML cells (4 individual patient AML) cultured 
on BM adipocytes or cultured alone and then 2x106 viable cells were injected into 
NSG mice. Engraftment was measured using human CD33 and human CD45. 
Shown in the flow figure are the characteristics of AML#12 engraftment into BM and 
spleen. In the dot plot each AML engraftment into NSG mice is shown for bone 
marrow and spleen, the engraftment of the AML cultured alone is shown by a 
shaded circle. The line through the data indicates the median. 
 
Figure 2. AML blasts induce adipocyte lipolysis. (A) Primary AML blasts or non-
malignant CD34+ cells were cultured alone or in co-culture with adipocytes for 24h, 
media was removed and used to detect free fatty acid and glycerol. Data 
represented as mean ± standard deviation (B) AML blasts incubated with media 
supplemented with BSA or media supplemented with 100µM of oleate-BSA 
conjugate for 2 days and AML blasts counted using flow cytometry and trypan blue 
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exclusion (n=4). The line through the data indicates the median (C) Immunoblot for 
pHSL from adipocytes cultured with and without AML blasts (n=4). Blots were 
repobed for total HSL and β-actin to show equal sample loading (D) Primary AML 
blasts in monoculture or cultured with adipocytes or BMSC with and without 
treatment with acipomox (APX) (10 μM) for 72 hours. AML blasts were counted using 
flow cytometry and trypan blue exclusion (n=4). The Mann-Whitney U test was used 
to determine statistical significance between treatment groups. Data represented as 
mean ± standard deviation (E) and (F) AML blasts cultured on adipocytes (with and 
without acipomox (10 μM)) or BMSC that had been pre-incubated with fluorescent 
dodecanoic acid analogue (DDA) for 24 h (n=4). Blasts were analysed for uptake of 
the fluorescent dodecanoic acid analogue by flow cytometry. Data represented as 
mean ± standard deviation. In panel (E) the red line is AML cultured on BMSC; the 
black, AML cultured on adipocytes and the blue, AML cultured on adipocytes treated 
with acipomox.  
 
Figure 3. FABP4 controls the transfer of lipids from adipocytes to AML. (A) 
AML blasts were cultured alone or with adipocytes or BMSC for 48h and then the 
adipocytes and BMSC were assessed for FABP4 mRNA expression using real-time 
PCR (n=6). non-malignant CD34+ cells were co-cultured alone or with adipocytes 
and FABP4 mRNA expression was measured. Data represented as mean ± 
standard deviation (B) Immunoblot for FABP4 from adipocytes cultured with and 
without AML blasts. Blots were reprobed for β-actin to show equal sample loading. 
(C) ELISA to detect FABP4 in media from adipocytes cultured alone or with AML 
blasts. Data represented as mean ± standard deviation. (D) AML blasts were 
cultured alone or with the addition of 2ug/ml of recombinant FABP4 (his-tagged) for 4 
h. Immunoblots were performed for FABP4 and His. Blots were reprobed for β-actin 
to show equal sample loading.  (E) Adipocytes were infected with FABP4-targeted 
shRNA or control shRNA lentivirus and after 72h analysed for FABP4 protein 
expression using Western Blotting. Blots were reprobed for β-actin to show equal 
sample loading. (F) Adipocytes were infected with FABP4-targeted shRNA or control 
shRNA lentivirus and after 72h preloaded with dodecanoic acid fluorescent fatty acid 
analogue and incubated with AML for 24h. AML blasts were analysed for 
fluorescence using flow cytometry (n=4). (G) Primary AML blasts or non-malignant 
CD34+ cells were cultured alone or co-cultured with adipocytes or BMSC with and 
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without treatment with FABP4 inhibitor for 72h. AML blasts were counted using flow 
cytometry and trypan blue exclusion (n=4).  Data represented as mean ± standard 
deviation. (H) Adipocytes were infected with FABP4 targeted shRNA or control 
shRNA lentivirus and after 72h were incubated with AML for 72h. AML blasts and 
non-malignant CD34+ cells were counted using flow cytometry and trypan blue 
exclusion (n=4). Data represented as mean ± standard deviation. 
 
Figure 4. AML derived FABP4 is crucial for blast survival in vivo. (A) FABP4 
gene expression (expressed in log2 RPKM values) was obtained from GSE49642 
and GSE48846 for non-malignant CD34+ cells, 22 blood AML and 21 bone marrow 
AML patient samples. P-value was obtained by Wilcoxon rank-sum test. Middle band 
denotes the median value with lower and upper bands denoting the first and third 
quartiles, respectively. (B) AML blasts were cultured alone or with adipocytes or 
BMSC for 48h before the AML were assessed for FABP4 mRNA expression using 
real-time PCR (n=6). Data represented as mean ± standard deviation. (C) Primary 
AML blasts were infected with FABP4 shRNA1 and shRNA2 and control shRNA and 
after 96h were subsequently cultured on adipocytes or BMSC for a further 72h. AML 
blasts counted using flow cytometry and trypan blue exclusion (n=4). Data 
represented as mean ± standard deviation. (D) Primary AML were infected with 
FABP4-targeted shRNA1 or control shRNA lentivirus and after 96h were cultured 
with adipocytes pre-loaded with dodecanoic acid fluorescent fatty acid analogue for 
24h. AML blasts were analysed for fluorescence using flow cytometry. (E) 
Hoxa9/Meis1 transformed cells (1x105/ml) were cultured normal media or normal 
media with IL-3, IL-6 and SCF supplemented or co-cultured on BMSC with normal 
media or on adipocytes with normal media.  Hoxa9/Meis1 expressing cells were 
counted using flow cytometry and trypan blue exclusion (n=4). Data represented as 
mean ± standard deviation. (F) Hoxa9/Meis1 expressing cells were infected with 
mouse FABP4 shRNA or control shRNA and after 72h analysed for FABP4 protein 
expression using Western Blotting. Blots were reprobed for β-actin to show equal 
sample loading.  (G) Hoxa9/Meis1 expressing cells were infected with FABP4 
targeted shRNA or control shRNA and after 72h incubated either alone, with 
cytokines, with BMSC or with adipocytes. Hoxa9/Meis1 expressing cells counted 
using flow cytometry and trypan blue exclusion (n=4). Data represented as mean ± 
standard deviation. (H) Hoxa9/Meis1 expressing cells were infected with FABP4 
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targeted shRNA or control shRNA lentivirus and after 72h incubated for 24h with 
adipocytes preloaded with dodecanoic acid fluorescent fatty acid analogue. 
Hoxa9/Meis1 expressing cells were analysed for fluorescence using flow cytometry 
(n=4). (I) Kaplan-Meier survival curves for C57BL/6 mice injected with Hoxa9/Meis1 
FABP4-KD cells or Hoxa9/Meis1 AML control-KD cells.  
 
Figure 5. Co-culture of AML with adipocytes activates β-oxidation in AML cells. 
(A) Primary AML blasts or non-malignant CD34+ cells were cultured on adipocytes 
for 3 days and then starved for 4h before measuring OCR (pMoles/min) using the 
Seahorse XFp Analyzer, at baseline and then after injection of palmitate (18 mins) 
and ETX (36 mins). Circles represent ETX (40μM) treatment and squares represent 
no ETX treatment. (B) Primary AML blasts or non-malignant CD34+ cells were 
cultured alone for 3 days and AML blasts cultured on adipocytes for 3 days and then 
starved for 4h. AML blasts were then treated with ETX (40μM) and OCR was 
measured as above (n=4). Data represented as mean ± standard deviation. (C) 
Primary AML blasts cultured alone for 3 days and AML blasts cultured on adipocytes 
or BMSC for 3 days and then starved for 4h. Data represented as mean ± standard 
deviation. (D) AML were infected with FABP4 targeted shRNA or control shRNA 
lentivirus and after 72h incubated with adipocytes or BMSC for 24h and OCR was 
measured in the AML (n=4). Data represented as mean ± standard deviation. (E) 
Primary AML blasts were in monoculture or co-cultured on adipocytes or BMSC with 
and without treatment with ETX for 72 hours. AML blasts were counted using flow 
cytometry and trypan blue exclusion (n=4). Data represented as mean ± standard 
deviation. (F) AML blasts were infected with CPT1A shRNA or control shRNA 
lentivirus and after 72 hours analysed for CPT1A mRNA and protein expression 
using RT-PCR and Western Blotting. Blots were reprobed for β-actin to show equal 
sample loading. Data represented as mean ± standard deviation. (G) AML were 
infected with CPT1A shRNA or control shRNA lentivirus and then co-cultured on 
BMSC or adipocytes. AML blasts were counted using flow cytometry and trypan blue 
exclusion (n=4). Data represented as mean ± standard deviation. (H)  2 Primary AML 
samples were infected with CPT1A shRNA or control shRNA lentivirus and after 96 
hours were then grown on adipocytes for 48 hours and subsequently 2x106 primary 
AML cells (n=4) were i.v. injected into NSG mice. Survival of the NSG mice is 
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represented by a Kaplan–Meier plot. P=0.025 for mice injected with AML CPT1-KD 
compared to AML control-KD mice. 
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